8-K: Avadel Pharmaceuticals Reports Strong LUMRYZ Sales Growth and Reaffirms 2025 Guidance

Avadel Pharmaceuticals announces positive Q4 2024 and full-year results, driven by a 158% year-over-year increase in LUMRYZ sales, and reiterates its 2025 financial guidance.

Summary

• Avadel Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2024.
• LUMRYZ generated $50.4 million in sales in Q4 2024, a 158% increase year-over-year, bringing the full-year total to $169.1 million.
• The company reiterates its 2025 guidance, expecting 3,300-3,500 patients on LUMRYZ by year-end.
• Avadel anticipates generating $240-$260 million in net product revenue and $20-$40 million in cash flow during 2025.
• Patient enrollment is progressing as planned in the Phase 3 REVITALYZ study for Idiopathic Hypersomnia (IH).
• The company reported a net loss for the year ended December 31, 2024 of $48.8 million, or ($0.51) per diluted share, compared to a net loss of $160.3 million, or ($2.00) per diluted share, for the same period in 2023.
• Cash flow was positive during the quarter ended December 31, 2024, resulting in cash, cash equivalents and marketable securities of $73.8 million compared to $65.8 million at September 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong sales growth of LUMRYZ, reaffirmed guidance, and progress in clinical trials. However, the net loss and ongoing search for a commercial leader temper the overall optimism.

Positives

• Significant growth in LUMRYZ sales, indicating strong market adoption.
• Reiteration of 2025 guidance, demonstrating confidence in future performance.
• FDA approval and Orphan Drug Exclusivity for LUMRYZ in pediatric patients.
• Positive cash flow in Q4 2024.
• Decrease in net losses for the year ended December 31, 2024 compared to the same period in 2023.

Negatives

• The company reported a net loss for the year ended December 31, 2024 of $48.8 million, or ($0.51) per diluted share.
• SG&A expenses increased for the quarter and year ended December 31, 2024 due to higher costs associated with the commercial launch of LUMRYZ and higher compensation costs due to increased headcount to support the execution of our strategy and plan.

Risks

• The company's business and operations are subject to significant risks, and, as a result, there can be no assurance that actual results and the results of the company's business and operations will not differ materially from the results contemplated in such forward-looking statements.
• The company is searching for a new leader of their commercial organization.

Future Outlook

Avadel expects to generate $240-$260 million in net product revenue and $20-$40 million in cash flow during 2025, with the number of patients on LUMRYZ expected to grow to 3,300-3,500.

Management Comments

• Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals, stated that the company has launched several initiatives since the start of the year with the primary goal of increasing the number of patients on LUMRYZ.
• Greg Divis mentioned that the company is encouraged by the positive trends that are developing and remain laser-focused on making the most of their opportunity in their pursuit of the billion-dollar market potential of LUMRYZ.
• Greg Divis noted that the company started 2025 with 2,500 patients on LUMRYZ and generated positive cash flow in the fourth quarter of 2024.

Industry Context

Avadel's focus on sleep medicine, particularly with LUMRYZ, positions it in a growing market addressing narcolepsy and idiopathic hypersomnia. The company's efforts to expand its sales and reimbursement teams reflect the competitive landscape and the need to ensure patient access to its medication.

Comparison to Industry Standards

• LUMRYZ competes with other narcolepsy treatments, including those from Jazz Pharmaceuticals (Xyrem, Xywav).
• The once-at-bedtime dosing of LUMRYZ offers a potential advantage over twice-nightly oxybate products like Xyrem.
• The $240-$260 million revenue guidance for 2025 suggests a significant growth trajectory compared to the $169.1 million in 2024, indicating a strong market penetration strategy.
• The company's focus on expanding into idiopathic hypersomnia with the REVITALYZ study could open up a new market segment, similar to how Jazz Pharmaceuticals expanded Xyrem's label.

Management Changes

Stakeholder Impact

• Shareholders can expect continued growth in revenue and potential profitability.
• Patients with narcolepsy and idiopathic hypersomnia may benefit from the continued development and commercialization of LUMRYZ.
• Employees may experience growth opportunities as the company expands its operations.

Next Steps

• Continue executing initiatives to accelerate patient demand for LUMRYZ.
• Complete patient enrollment in the Phase 3 REVITALYZ study during the second half of 2025.
• Further strengthen the management team and find a new commercial organization leader.
• Seek and obtain FDA approval for, as well as, commercially launch LUMRYZ for indications beyond narcolepsy.

Key Dates